Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study

D. ALMENAR, MD, Department of Oncology, Hospital Universitario Dr Peset, Valencia, J. MAYANS, MD, Department of Hematology, Hospital Arnau de Vilanova, Valencia, O. JUAN, MD, Department of Oncology, Hospital Arnau de Vilanova, Valencia, J.M. GARCIA BUENO, MD, Department of Oncology, Hospital General Universitario, Albacete, J.I. JALON LOPEZ, MD, Department of Oncology, Clínica Riber, Madrid, A. FRAU, MD, PhD, Department of Oncology, Hospital Provincial de Castellón. Castellón, M. GUINOT, MD, Department of Hematology, Hospital General de Castellón, Castellón, P. CEREZUELA, MD, Department of Oncology, Hospital Santa María del Rosell, Cartagena, E. GARCIA BUSCALLA, bsc, Medical Department, Amgen S.A., Barcelona, J.A. GASQUET, PhD, Medical Department, Amgen S.A., Barcelona, & J. SANCHEZ, msc, Medical Department, Amgen S.A, Barcelona, Spain

ALMENAR D., MAYANS J., JUAN O., GARCIA BUENO J.M., JALON LOPEZ J.I., FRAU A., GUINOT M., CEREZUELA P., GARCIA BUSCALLA E., GASQUET J.A. & SANCHEZ J. (2009) European Journal of Cancer Care 18, 280–286

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study

Daily granulocyte colony-stimulating factors [G-CSFs]; e.g. filgrastim, lenograstim] are frequently used to reduce the duration of chemotherapy-induced neutropenia (CIN) and the incidence of febrile neutropenia (FN) in cancer patients. A pegylated formulation of filgrastim, pegfilgrastim, which is administered once per cycle, was introduced in Spain in 2003. LEARN was a multi-centre, retrospective, observational study in Spain comparing patterns of use of daily G-CSF and pegfilgrastim, and CIN-related outcomes in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy. Outcome measures were the percentage of patients receiving G-CSF for primary prophylaxis versus secondary prophylaxis/treatment, duration of treatment with G-CSF and pegfilgrastim, and CIN-related outcomes in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy. Outcome measures were the percentage of patients receiving G-CSF for primary prophylaxis versus secondary prophylaxis/treatment, duration of treatment with G-CSF and incidence of CIN-related complications. Medical records from consecutive patients with documented pegfilgrastim \( n = 75 \) or daily G-CSF \( n = 111 \) use during 2003 were included. The proportion of patients receiving primary or secondary prophylaxis was comparable between the pegfilgrastim \( 39 \) and \( 48 \)\% respectively] and daily G-CSF \( 40 \) and \( 48 \)% respectively) groups. However, there was a trend towards less frequent use to treat a neutropenic event such as FN or neutropenia in the pegfilgrastim group \( 17 \) versus \( 30 \)% with daily G-CSF). Chemotherapy-induced neutropenia-related complications were less frequent in patients receiving pegfilgrastim [e.g. FN 11 versus 24% with daily G-CSF]. This is the first study to show the potential benefits of pegfilgrastim over daily G-CSF in Spanish clinical practice.

Keywords: pegfilgrastim, G-CSF, pattern of use, neutropenia, febrile neutropenia.
INTRODUCTION

Chemotherapy-induced neutropenia (CIN) is the most common dose-limiting toxicity of cancer chemotherapy. Patients receiving myelosuppressive chemotherapy frequently develop severe grade 3 or 4 neutropenia or febrile neutropenia (FN), which can make them susceptible to the development of potentially life-threatening infections [Dale et al. 2001; Aapro et al. 2006, Smith et al. 2006].

Historically, the principal strategies for managing CIN are reducing the dose intensity and total dose of the chemotherapy. In the case of FN, a medical emergency, hospitalization is generally required, with the administration of antibiotics to combat infection. It is, however, well documented that reducing or delaying the chemotherapy dose can compromise treatment outcomes and ultimately patient survival [Bonadonna et al. 1995; Budman et al. 1998]. Moreover, use of antibiotics can be lifesaving but may be associated with adverse effects and the emergence of resistant pathogens [Yoshida & Ohno 2004].

The introduction of granulocyte colony-stimulating factors (G-CSFs) over a decade ago has had a significant impact on the management of myelotoxicity associated with cancer chemotherapy. Daily subcutaneous doses of G-CSFs such as filgrastim [Neupogen®, Amgen, Inc., Thousand Oaks, CA, USA] and lenograstim [Granocyte®, Chugai Sanofi-Aventis, Paris, France] are now commonly used in clinical practice to reduce the incidence, duration and severity of CIN, the incidence of FN, and the risk of infection in patients undergoing myelosuppressive chemotherapy [Crawford et al. 1991; Trillet-Lenoir et al. 1993].

Guidelines published by the National Comprehensive Cancer Network recommend the routine prophylactic use of CSFs to prevent the development of FN in patients in whom the risk of developing FN or a neutropenic event compromising treatment with systemic chemotherapy is 20% or higher [defined as ‘high-risk’ patients] [Crawford et al. 2005; Lyman 2005]. Updated guidelines from the American Society for Clinical Oncology and from the European Organization for Research and Treatment of Cancer also recommend the use of CSFs in patients on regimens associated with a 20% or greater risk of FN [Aapro et al. 2006, Smith et al. 2006]. Where the risk of FN is 10–20%, patient-related factors such as age should be taken into account when deciding whether G-CSFs are required. Using prophylactic G-CSF support, planned chemotherapy doses can be administered on time, more frequently and at the desired intensity, thus optimizing the outcome for the patient [Lyman et al. 2002].

The use of pegylation technology has created a new molecule, pegfilgrastim [Neulasta®, Amgen, Inc.], with a significantly improved pharmacokinetic profile compared with daily filgrastim. Pegfilgrastim is produced by the covalent attachment of a 20-kDa polyethylene glycol moiety to the N-terminal methionine residue of filgrastim. Pegylation results in reduced renal clearance of pegfilgrastim compared with filgrastim, leaving neutrophil receptor-mediated clearance as the dominant clearance mechanism [Johnston et al. 2000]. This self-regulated nature of pegfilgrastim ensures a sustained serum concentration of pegfilgrastim during the period of neutropenia and allows the administration of a single dose of pegfilgrastim per cycle of chemotherapy, in contrast to the requirement for a daily subcutaneous injection of filgrastim [Johnston et al. 2000, Green et al. 2003].

Clinical trials have shown that a single fixed subcutaneous dose of pegfilgrastim 6 mg or 100 μg/kg is comparable in safety and efficacy to daily injections of filgrastim for reducing the duration of severe CIN following myelosuppressive chemotherapy in patients with cancer [Holmes et al. 2002a,b, Green et al. 2003].

The introduction of pegfilgrastim into clinical use in Spain in 2003 may have had an impact on the pattern of use of daily G-CSFs – whether used for prophylaxis or for treatment – and the CIN-related outcomes of chemotherapy patients. Here, we report the results of a Spanish study that compared the usage patterns of daily G-CSF and pegfilgrastim, and the respective outcomes in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy.

PATIENTS AND METHODS

The LEARN Study was a multi-centre, retrospective, observational study of patients with non-myeloid tumours who underwent cytotoxic chemotherapy supported by G-CSF treatment. Consecutive medical records from patients with documented treatment with either daily G-CSF or pegfilgrastim over the same time period were obtained from 10 Spanish centres during 2003. The study was approved by the Ethics Committees at all participating centres.

From the medical records obtained, the following data were recorded for each patient on standard data collection forms: demographic details, diagnosis and classification of their cancer, previous radiotherapy and chemotherapy treatment; current radiotherapy and chemotherapy treatment; haematological toxicity associated with chemotherapy [neutropenia]; usage pattern of G-CSF [proactive [primary prophylaxis] versus reactive [secondary prophylaxis/treatment]]; and the incidence of bone pain and other adverse effects relating to the G-CSF used.
The outcome measures assessed were: the proportion of patients with proactive versus reactive use of G-CSFs; the duration of treatment with daily G-CSF; and the incidence of CIN-related outcomes. The CIN-related outcomes measured were: delay or reduction in dose (>3 days delay with respect to planned date of administration; <85% of planned dose administered); incidence of FN; incidence of hospitalization; and antibiotic use (type, dose and duration).

Statistical analysis was descriptive in nature. Categorical end points are summarized by the number and percentage of individuals in each category. Continuous end points are summarized by means and standard deviations. Two-sided 95% confidence intervals are presented where appropriate.

RESULTS

Baseline characteristics

Records from a total of 248 patients with documented pegfilgrastim or daily G-CSF use during their chemotherapy were included in the study. A total of 75 (30%) patients received pegfilgrastim only, and 111 (45%) patients received daily G-CSF only [99 received filgrastim and 12 received lenograstim]. A total of 62 (25%) patients received both daily G-CSF and pegfilgrastim. These patients were treated in the immediate period following the introduction of pegfilgrastim in Spain when physicians were unfamiliar with using a long-acting G-CSF. Due to the heterogeneity of their management, these 62 patients were excluded from analyses of G-CSF usage and chemotherapy-related complications.

The demographic characteristics and cancer diagnoses of the patients included in the study are shown in Table 1. There were no observed differences in demographic characteristics between the treatment groups. Overall, the most common tumour types were lung (25% of all patients), breast (20%) and malignant lymphomas (20%).

The previous chemotherapy and radiotherapy treatments of patients included in the study are shown in Table 2. The majority of patients in each treatment group had previously received first-line chemotherapy or were currently receiving first-line chemotherapy. Current chemotherapy regimens for the most common tumour types [breast, lung, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and myeloma] are shown in Table 3.

Pattern of G-CSF use

The median number of cycles of chemotherapy per patient was the same in both the daily G-CSF- and pegfilgrastim-treated patients [4 (range 1–13); 4 (range 1–16) respectively]. Similarly, the median number of cycles of chemotherapy in which patients received G-CSF was also the same in both the daily G-CSF- and pegfilgrastim-treated patients [2 (range 1–8); 2 (range 1–7) respectively].

The pattern of G-CSF use among the patients in the study is shown in Table 4. The percentage of patients receiving primary or secondary prophylaxis was comparable between the pegfilgrastim and daily G-CSF groups. However, a potential trend was observed towards less frequent use as treatment in the pegfilgrastim group [17%] compared with the daily G-CSF group [30%].

In the daily G-CSF group, the median number of injections per cycle was comparable, irrespective of whether
daily G-CSF was used as primary prophylaxis (6 injections; range 1–13), secondary prophylaxis (5 injections; range 1–11) or treatment (5 injections; range 1–11).

CIN-related complications
The incidence of chemotherapy-related complications in cancer patients receiving either pegfilgrastim or daily G-CSF is shown in Table 5. Patients who were treated with pegfilgrastim appeared to have a numerically lower incidence of dose reduction due to neutropenia, FN, hospitalization due to FN and antibiotic administration than those who received daily G-CSF. However, due to the descriptive nature of the analysis in this study, a conclusion of the significance cannot be made.

Adverse reactions due to G-CSF therapy
A low incidence of adverse reactions considered by the investigator to be due to G-CSF treatment was observed. Three patients (2.7%) in the daily G-CSF group experienced bone pain compared with one (1.3%) in the pegfilgrastim-treated group. Treatment-related adverse reactions other than pain were reported in six patients (5.4%) and one patient (1.3%) respectively.

DISCUSSION
In this study of everyday clinical practice in Spain, use of daily G-CSFs and pegfilgrastim followed a similar pattern with respect to primary and secondary prophylaxis, but there was a potential trend towards less frequent use of
pegfilgrastim as treatment for FN or CIN. Chemotherapy-induced neutropenia-related complications, including FN, appeared to be less frequent in patients receiving pegfilgrastim than in those receiving daily G-CSF.

Granulocyte colony-stimulating factor prophylaxis reduces the risk of developing CIN, thereby reducing associated morbidity and mortality. Reducing CIN also has the potential to reduce hospitalization and treatment costs, as well as reducing the requirement for dose reductions or treatment delays, which may themselves compromise clinical outcomes [Aapro et al. 2006; Smith et al. 2006]. As previously mentioned, new guidelines on the use of G-CSFs recommend primary prophylaxis from the first cycle of chemotherapy for all patients with an overall risk of developing FN of 20% or higher (Aapro et al. 2006; Smith et al. 2006). Secondary G-CSF prophylaxis may be given to patients who have had a prior episode of FN in order to prevent subsequent neutropenic complications.

As indicated by the new guidelines, the efficacy of prophylactic G-CSFs for reducing the incidence, duration and intensity of neutropenia is well established with a variety of chemotherapeutic regimens and tumour types [Crawford et al. 1991, 2005; Trillet-Lenoir et al. 1993; Green et al. 2003; Lyman 2005]. Data from individual randomized clinical trials (RCTs) have been supported by results from meta-analyses, which have also demonstrated that G-CSF use reduces the incidence and duration of FN-related hospitalization [Holmes et al. 2002b], as well as the need for antibiotic treatment and the risk of infection-related mortality (Kuderer et al. 2007).

In the largest double-blind, randomized, placebo-controlled multi-centre study of prophylactic pegfilgrastim support reported to date, women with breast cancer receiving docetaxel chemotherapy (a regimen associated with an expected FN incidence of 20%) were randomized to receive either placebo (n = 465) or pegfilgrastim (n = 463) administered 24 h after chemotherapy (Vogel et al. 2005). The placebo group had an overall incidence of FN of 17% compared with 1% in the pegfilgrastim group. In addition, in the pegfilgrastim and placebo groups, respectively, the incidence of hospitalization was 1% versus 14%, and the use of intravenous antibiotics was 10% versus 2% (P < 0.001 in each case). Several large comparative RCTs have demonstrated the equivalent efficacy and safety of pegfilgrastim and filgrastim. In two pivotal trials with a similar design, a single fixed dose of pegfilgrastim [6 mg (n = 77) or 100 μg/kg (n = 149)] was compared with daily filgrastim (5 μg/kg/day; n = 222) as prophylactic G-CSF support in a total of 467 women with breast cancer receiving doxorubicin and docetaxel chemotherapy. The incidences of FN with filgrastim were 20 and 18% in the two studies compared with 13 and 9% for patients receiving pegfilgrastim (Holmes et al. 2002a; Green et al. 2003). Indeed, the pooling of data from these two trials in a combined analysis suggests that the risk of FN was significantly lower for pegfilgrastim compared with filgrastim (relative risk = 0.56) [Siena et al. 2003].

Clinical studies in patients with solid tumours and lymphomas have shown that a median of 11 injections of daily filgrastim per cycle is required to achieve a reduction in the incidence of grade 4 neutropenia equivalent to that associated with a single injection of pegfilgrastim [Holmes et al. 2002a; Green et al. 2003; Siena et al. 2003; Vose et al. 2003]. A median of 16 injections may be required in patients with acute myeloid leukaemia (Bosi et al. 2004; Sierra et al. 2008). In clinical practice, however, there is a tendency to reduce the number of days of G-CSF given per cycle (e.g. to 5 or 6 days). The timing and duration of G-CSF administration following chemotherapy has significant effects on haematological recovery and on the incidence of infections. Studies have shown that FN and infections are more likely to occur during chemotherapy cycles that use a reduced number of days of G-CSF prophylaxis [Crawford et al. 1997; Koumakis et al. 1999; Kloess et al. 2003; Mucenski & Shogan 2003; Scott et al. 2003]. For example, in an analysis of data from a large breast cancer study, pegfilgrastim was compared with current practice use of G-CSF on days 5-10 of each cycle. The incidence of FN was 7% among patients receiving

### Table 5. The incidence of chemotherapy-related complications in cancer patients receiving either pegfilgrastim or daily G-CSF

| Chemotherapy-related complications | Daily G-CSF (n = 111) | Pegfilgrastim (n = 75) |
|-----------------------------------|-----------------------|-----------------------|
| Dose delay                        | 51, 46.0 [36.0; 55.0] | 33, 44.0 [33.0; 55.0] |
| Dose reduction                    | 23, 20.7 [14.2; 29.2] | 11, 14.7 [8.2; 24.6]  |
| Dose reduction due to neutropenia | 23, 20.7 [14.1; 29.2] | 5, 6.7 [2.5; 15.0]    |
| Febrile neutropenia               | 27, 24.3 [17.2; 33.1] | 8, 10.7 [5.3; 19.9]   |
| Hospitalization due to febrile neutropenia | 22, 19.8 [13.4; 28.3] | 7, 9.3 [4.3; 18.3]    |
| Antibiotic consumption due to febrile neutropenia | 19, 17.1 [11.2; 25.3] | 6, 8.0 [3.4; 16.7]    |

CI, confidence interval; G-CSF, granulocyte colony-stimulating factor.
pegfilgrastim compared with 18% for current practice G-CSF use (Von Minckwitz et al. 2008). In the present LEARN study, the median number of injections of G-CSF per cycle was also 5–6. Here, too, there was an indication of superior protection from CIN with pegfilgrastim than with current practice G-CSF use; however, as this was a non-randomized study, this finding must be interpreted with caution.

In addition to its beneficial impact on health outcomes, data suggest that pegfilgrastim is a cost-effective treatment. Based on the findings of pivotal trials, a health economic model from Spain has shown that primary prophylaxis with pegfilgrastim was more cost-effective than 11 days of filgrastim treatment in breast cancer patients [Mayordomo et al. 2006].

The trend in the current study towards less frequent use of pegfilgrastim as treatment for CIN is unsurprising since physicians were likely to prefer the flexibility of daily dosing in this setting, especially if FN occurred late in the cycle when use of a long-acting dose of pegfilgrastim would potentially overlap with a subsequent chemotherapy cycle. In any case, the routine therapeutic use of G-CSFs is not recommended [Aapro et al. 2006].

In summary, LEARN is the first study to compare patterns of pegfilgrastim and G-CSF use in clinical practice in Spain. Our data reveal that soon after its introduction, pegfilgrastim was being administered as primary and secondary prophylaxis in similar proportions of patients and in similar numbers of cycles to daily G-CSF when used for this purpose. As expected, uptake of pegfilgrastim for the treatment of neutropenia was less marked. Importantly, this study indicates that daily G-CSF prophylaxis was given for only around 5–6 days per cycle in many patients, possibly compromising protection against CIN and related events. Our findings support those of other authors, suggesting that pegfilgrastim given once per cycle may be more efficacious than daily G-CSF administered according to current practice. Such findings would need to be confirmed in further, prospective studies.

ACKNOWLEDGEMENTS

Ten centres at seven institutions participated in the study: Oncology Department, H. Doctor Peset, Valencia; Hematology Department, H. Doctor Peset, Valencia; Oncology Department, H. Arnau de Vilanova, Valencia; Hematology Department, H. Arnau de Vilanova, Valencia; Oncology Department, Policlínica Miramar, Palma de Mallorca; Oncology Department, Clínica Rúbén, Madrid; Oncology Department, H. Provincial, de Castellón, Castellón; Hematology Department, H. General, Castellón; Oncology Department, H. Santa María del Rosell, Cartagena; Hematology Department, H. Santa María del Rosell, Cartagena, Spain. The authors wish to acknowledge Parexel MMS for medical writing services in the preparation of this manuscript. The study was supported by Amgen S.A. Esther García Buscallá, José Antonio Gasquet and Jordi Sánchez are employees of Amgen S.A.

REFERENCES

Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., Kearney N., Lyman G.H., Tjan-Heijnen V.C., Walewski J., Weber D.C., Zielinski C. & The European Organisation for Research and (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 42, 2433–2453.

Bonadonna G., Valagussa P., Moliterni A., Zambetti M. & Brambilla C. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. The New England Journal of Medicine 332, 901–906.

Bosi A., Szer J., Kassis J., Sierra J., Desborough C. & Buchanan K. (2004) A multicenter, double-blind, randomized, Phase II trial comparing pegfilgrastim with filgrastim as an adjunct to chemotherapy for acute myeloid leukaemia [AML]. Blood 104 [Suppl. 11], 247A.

Budman D.R., Berry D.A., Cirrincione C.T., Henderson I.C., Wood W.C., Weis R.B., Ferrer C.R., Muss H.B., Green M.R., Norton L. & Frei E. 3rd. (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. Journal of the National Cancer Institute 90, 1205–1211.

Crawford J., Ozor H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Piccozzi V., Rausch G., Smith R., Gradishar W., Yahanda A., Vincent M., Stewart A. & Glasy J. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. The New England Journal of Medicine 325, 164–170.

Crawford J., Kreisman H., Garewal H., Jones S.E., Shoemaker D., Pupa M.R., Armstrong S., Tomita D. & Dziem G. (1997) The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Annals of Oncology 8, 117–1124.

Crawford J., Althaus B., Armitage A., Blayney D.W., Cataland S., Dale D.C., Demetri G.D., Foran J., Henney M.L., Hoyo S., Kloth D.D., Lyman G.H., Michaud L., Motl S., Vadhan-Raj S. & Wong M.K. & National Comprehensive Cancer Network (2005) Myeloid growth factors clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 3, 540–555.

Dale D., Crawford J. & Lyman G. (2001) Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review. Proceedings of the American Society of Clinical Oncology 20, 410a. [Abstract 1638].

Green M., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., Siena S., Lalinsang R.I., Samonig H., Clemens M.R., Zani V., Liang B.C., Renwick J., Piccart M.J. & International Pegfilgrastim 749 Study Group (2003) A randomized, double-blind, multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology 14, 29–35.

© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd
Holmes F.A., O'Shaughnessy J.A., Vukelja S., Jones S.E., Shogan J., Savin M., Glaspy J., Moore M., Meza L., Wiznitzer I., Neumann T.A., Hill L.R. & Liang B.C. (2002a) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. *Journal of Clinical Oncology* 20, 727–731.

Holmes F.A., Jones S.E., O'Shaughnessy J.A., Vukelja S., George T., Savin M., Richards D., Glaspy J., Meza L., Cohen G., Dhami M., Budman D.R., Hackett J., Grassard M., Yang B.B. & Liang B.C. (2002b) Comparable efficacy and safety profiles on once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. *Annals of Oncology* 13, 903–909.

Johnston E., Crawford J., Blackwell S., Bjurstrom T., Lockbaum K., Koumakis G., Vassilomanolakis M., Barbounis V., Hatzichristou F.A., Jones S.E., O'Shaughnessy J.A., Vukelja S., George Mucenski J.W. & Shogan J.E. (2003) Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor. *Journal of Managed Care Pharmacy* 9 (Suppl. 2), 10–14.

Scott S.D., Chrischilles E.A., Link B.K., Delgado D.J., Fridman M. & Stolshek B.S. (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. *Journal of Managed Care Pharmacy* 9 (Suppl. 2), 15–21.

Siena S., Piccart M.J., Holmes F.A., Glaspy J., Hackett J. & Renwick J.J. (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II–IV breast cancer. *Oncology Reports* 10, 715–724.

Sierra J., Szer J., Kassis J., Herrmann R., Lazzarino M., Thomas X., Noga S.J., Baker N., Dansey R. & Bosi A. (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients with low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. *BMC Cancer* (in press).

Smith T.J., Khathaweesaran J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., Bennett C.L., Cantor S.B., Crawford J., Cross S.J., Demetri G., Desch C.E., Pizzo P.A., Schiffer C.A., Schwartzberg L., Sommerfield M.R., Somlo G., Wade J.C., Wade J.L., Winn R.J., Wozniak A.J. & Wolff A.C. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline. *Journal of Clinical Oncology* 24, 3187–3205.

Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzeimeier U., Lebeau B., Depierre A., Johnson P., Decoster G., Tomita D. & Ewen C. (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. *European Journal of Cancer* 29A, 319–324.

Vogel C.L., Wojtkiewicz M.Z., Carroll R.R., Tjulandin S.A., Schwartzberg L., Sommerfield M.R., Somlo G., Wade J.C., Wade J.L., Winn R.J., Wozniak A.J. & Wolff A.C. (2006) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. *Journal of Clinical Oncology* 23, 1178–1184.

Von Minckwitz G., Kummel S., du Bois A., Eiermann W., Eidtmann H., Gerber B., Hilfrich J., Huober J., Costa S.D., Jackisch C., Grasshoff S.-T., Vescia S., Skacel T., Loibl S., Mehta K.M. & Kaufmann M. (2008) Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC [docetaxel/doxorubicin/cyclophosphamide] chemotherapy for breast cancer. Results from the GEPARTRIO study. *Annals of Oncology* 19, 292–298.

Vose J.M., Crump M., Lazarus H., Emmanouilides C., Schenkel D., Moore J., Frankel S., Finn I., Lovelace W., Hackett J. & Liang B.C. (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. *Journal of Clinical Oncology* 21, 514–519.

Yoshida M. & Ohno R. (2004) Antimicrobial prophylaxis in febrile neutropenia. *Clinical Infectious Diseases* 39 (Suppl. 1), S65–S67.